Roche/Genentech will "make a portfolio decision" on development of the novel Hedgehog inhibitor GDC-0449 in advanced ovarian cancer after further analyses of Phase II data, partner Curis said Aug. 9. Early analyses of top-line data "warrant additional investigation to clarify and interpret potential clinical activity," the company said. The news isn't as ominous as it might sound, Dan Passeri, the Cambridge, Mass., biotech's CEO, said in an interview. "There is a suggestion of some clinical signal...